Clinical Trial Detail

NCT ID NCT02927769
Title A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Nivolumab

Brentuximab vedotin + Bendamustine

Age Groups: adult child

No variant requirements are available.